Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)—are approved in Europe for metastatic colorectal cancer. Cyramza and Lonsurf are recent additions to the treatment armamentarium, and further options look set to penetrate the market in the next few years. Ever-increasing and ever-more-costly treatment options, as well as the evolution of biomarker-driven prescribing for colorectal cancer, and the costs that go with it, mean oncologists are striving to optimize the treatment algorithm and maximize treatment outcome for patients, while payers are balancing clinical need with economic constraints. This research analyzes the evolving prescribing landscape for metastatic colorectal cancer, and the impact of payer policy upon it.

Questions Answered

  • What are the current drivers of and barriers to prescribing of key brands for mCRC, and what are the main cost-related and clinical constraints on uptake?
  • How do European product labeling and national, regional, and local reimbursement restrictions differentially impact use of key brands in mCRC?
  • How might evolving healthcare reforms and cost-containment strategies affect reimbursement of novel agents? How challenging will country– and region-specific prescribing constraints be for uptake of these therapies?
  • To what extent will oncologists and payers embrace the costly emerging agents Keytruda (Merck & Co.), triplet combination binimetinib, encorafenib, and Erbitux (Array BioPharma/Pierre Fabre/Merck KGaA), and Tecentriq plus Cotellic (Roche)?

Product Description

Access & Reimbursement: Provides in-depth insight into the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Key Updates
      • December 2017
    • Market Access Overview
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for Colorectal Cancer Therapies in the EU5
    • Successes and Stumbles
      • Successes and Stumbles Among Metastatic Colorectal Cancer Therapies in the EU5
    • Key Stakeholders in the Road to Market Access
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
    • Key Market Access Roadblocks
    • Reimbursement Dynamics
      • France
        • France: Crucial HTA Criteria
        • France: Reimbursement Regulations and Prescribing Parameters
      • Germany
        • Germany: Crucial HTA Criteria
        • Germany: Reimbursement Regulations and Prescribing Parameters
      • Italy
        • Italy: Crucial HTA Criteria
        • Italy: Reimbursement Regulations and Prescribing Parameters
      • Spain
        • Spain: Crucial HTA Criteria
        • Spain: P&R Drivers and Key HTA Considerations
        • Spain: Reimbursement Regulations and Prescribing Parameters
      • United Kingdom
        • United Kingdom: Crucial HTA Criteria
        • United Kingdom: Reimbursement Regulations and Prescribing Parameters
    • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
      • Prescriber Preferences for Metastatic Colorectal Cancer
        • Prescriber Preferences for First-Line Metastatic Colorectal Cancer
        • Prescriber Preferences for Second-Line Metastatic Colorectal Cancer
        • Prescriber Preferences for Third- and Later-line Metastatic Colorectal Cancer
      • Impact of Payer Policy on Prescribing for Metastatic Colorectal Cancer
        • Overall Impact of EU5 Payer Policy on Prescribing for Metastatic Colorectal Cancer
        • Impact of Country-Specific Payer Policy on Prescribing for Metastatic Colorectal Cancer
      • Top Prescribing Drivers in Metastatic Colorectal Cancer
        • Top Prescribing Drivers of Therapies for Metastatic Colorectal Cancer
    • Market Access Landscape for Emerging Therapies
      • Likely Impact of Emerging Therapies for Metastatic Colorectal Cancer
        • Expected Uptake of Emerging Therapies for Metastatic Colorectal Cancer
        • Likely Impact of Emerging Metastatic Colorectal Cancer Therapies on Currently Used Treatments
      • Market Access Challenges for Emerging Metastatic Colorectal Cancer
        • Factors Expected to Limit Prescribing of Emerging Metastatic Colorectal Cancer Therapies
        • Physician Perspective on Use of and Challenges for Keytruda and Tecentriq
      • Payer Opinion on Emerging Therapies for Metastatic Colorectal Cancer
    • Methodology
      • Primary Research Design
      • Physician Demographics and Practice Setting
    • Appendix
      • Country-Specific Reimbursement Background Details
        • France: Reimbursement Background
        • Germany: Reimbursement Background
        • Italy: Reimbursement Background
        • Spain: Reimbursement Background
        • United Kingdom: Reimbursement Background
      • Key Current and Emerging Therapies for Metastatic Colorectal Cancer
        • Emerging Therapy Profiles
      • Physician Survey Data

Author(s): Yulia Privolnev, MA

Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Yulia’s specific focus is on all aspects of market access in Western and Eastern Europe, as well as external reference pricing (ERP) and managed entry agreements (MEAs) on a global scale. Yulia holds a bachelor’s degree from the University of Toronto and a master’s degree from the London School of Economics.


Related Reports

Colorectal Cancer | Geographic Focus - China | Colorectal Cancer - China In-Depth - China

MARKET OUTLOOK Colorectal cancer, a major public health concern in China, is expected to become the second most common form of cancer there by 2028, behind only lung can...

View Details

Colorectal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is...

View Details

Colorectal Cancer | Epidemiology | Emerging Markets

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....

View Details

Colorectal Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Market Outlook Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) ar...

View Details